EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

45432 reported adverse events

Drug classes: Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

These side effects are most commonly reported by patients taking EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE:

# Side effect Count
0 BONE DENSITY DECREASED 16618
1 CHRONIC KIDNEY DISEASE 10394
2 OSTEONECROSIS 9164
3 BONE LOSS 9115
4 RENAL FAILURE 9049
5 MULTIPLE FRACTURES 8191
6 TOOTH LOSS 8163
7 RENAL INJURY 8010
8 OSTEOPOROSIS 7326
9 SKELETAL INJURY 7181
See all common reactions for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 SKELETAL INJURY 7181 0.6937
1 BONE LOSS 9115 0.6057
2 BONE DEMINERALISATION 636 0.6006
3 ULTRASOUND ANTENATAL SCREEN 53 0.5521
4 BONE DENSITY DECREASED 16618 0.5299
5 CLOACAL EXSTROPHY 30 0.5085
6 MULTIPLE FRACTURES 8191 0.4981
7 TOOTH INJURY 2095 0.4821
8 BLADDER AGENESIS 31 0.4189
9 TOOTH LOSS 8163 0.3933
See all enriched reactions for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE